4. it will be possible to reduce the subsequent costs of preventative cervical cancer screening. The Bethesda system has been used in the USA for 25 years and there is not a single study which has evaluated any one of these 4 points listed in the "Conclusions to Munich Nomenclature III". According to personal communications by wellknown American researchers who have worked extensively on TBS such as Diane Solomon [2] , Walter Kinney, Mark Stoler and Massad Stewart [3] , such studies have not been and will not be carried out.
We therefore suggest that the authors remove the "Conclusions" and develop a scientific concept which can be used to show whether the abovelisted 4 hypotheses can be proven. Each of the 19(!) possible diagnostic groups listed in Munich Nomenclature III is accompanied by recommendations which are peppered with terms such as "as the case may be", "possibly", "and/or", "in special casesʼ, "additive methods". The TBS includes no recommendations whatsoever; our colleagues in the USA who have been using the TBS since 1988 can refer to consensus guidelines which are regularly updated, most recently in 2012, and which offer recommendations on how to examine and treat different TBS groups. In these guidelines, the 10 TBS groups used to describe epithelial changes (compared to 17(!) groups in Munich Nomenclature III) are divided into additional subgroups for " women aged between 21-24 years and between 30-64 years, " pregnant women, " postmenopausal women, " women with positive or negative HPV results or who tested positive for HPV-16 or -18, and " women with a previous history of cytologically abnormal smears. The consensus guidelines conclude that "electronic medical records and computers hold great promise for assisting clinicians and patients in negotiating the complexity" of the many different potential options. We therefore propose that Munich Nomenclature III should be simplified in analogy to the TBS and that all recommendations should be removed. An S3 Guideline "Prevention of Cervical Cancer" is currently being compiled with differentiated and practicable recommendations for the respective diagnoses which also take account of the specific framework of our healthcare system (including the use and availability of biological markers, experience with colposcopy, the expectations of pa-
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